Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome Endocrinopathy) and ROSE II trials.
Tsuboi H, Toko H, Honda F, Abe S, Takahashi H, Yagishita M, Hagiwara S, Ohyama A, Kondo Y, Nakano K, Tanaka Y, Shimizu T, Nakamura H, Kawakami A, Fujieda Y, Atsumi T, Suzuki Y, Kawano M, Nishina N, Kaneko Y, Takeuchi T, Kobayashi H, Takei M, Ogasawara M, Tamura N, Takasaki Y, Yokota K, Akiyama Y, Mimura T, Murakami K, Mimori T, Ohshima S, Azuma N, Sano H, Nishiyama S, Matsumoto I, Sumida T. Tsuboi H, et al. Among authors: fujieda y. Mod Rheumatol. 2023 Jan 3;33(1):160-168. doi: 10.1093/mr/roac011. Mod Rheumatol. 2023. PMID: 35134994
Maintenance treatment using abatacept with dose reduction after achievement of low disease activity in patients with rheumatoid arthritis (MATADOR) - A prospective, multicenter, single arm pilot clinical trial.
Yasuda S, Ohmura K, Kanazawa H, Kurita T, Kon Y, Ishii T, Fujieda Y, Jodo S, Tanimura K, Minami M, Izumiyama T, Matsumoto T, Amasaki Y, Suzuki Y, Kasahara H, Yamauchi N, Kato M, Kamishima T, Tsutsumi A, Takemori H, Koike T, Atsumi T. Yasuda S, et al. Among authors: fujieda y. Mod Rheumatol. 2017 Nov;27(6):930-937. doi: 10.1080/14397595.2017.1286714. Epub 2017 Feb 16. Mod Rheumatol. 2017. PMID: 28150514 Clinical Trial.
Interferon-inducible Mx1 protein is highly expressed in renal tissues from treatment-naïve lupus nephritis, but not in those under immunosuppressive treatment.
Shimizu Y, Yasuda S, Kimura T, Nishio S, Kono M, Ohmura K, Shimamura S, Kono M, Fujieda Y, Kato M, Oku K, Bohgaki T, Fukasawa Y, Tanaka S, Atsumi T. Shimizu Y, et al. Among authors: fujieda y. Mod Rheumatol. 2018 Jul;28(4):661-669. doi: 10.1080/14397595.2017.1404711. Epub 2017 Nov 30. Mod Rheumatol. 2018. PMID: 29189089
Autologous haematopoietic stem cell transplantation for Japanese patients with systemic sclerosis: Long-term follow-up on a phase II trial and treatment-related fatal cardiomyopathy.
Nakamura H, Odani T, Yasuda S, Noguchi A, Fujieda Y, Kato M, Oku K, Bohgaki T, Sugita J, Endo T, Teshima T, Atsumi T. Nakamura H, et al. Among authors: fujieda y. Mod Rheumatol. 2018 Sep;28(5):879-884. doi: 10.1080/14397595.2017.1416920. Epub 2018 Jan 8. Mod Rheumatol. 2018. PMID: 29251023 Clinical Trial.
Has lupus anticoagulant testing had its day?
Fujieda Y, Atsumi T. Fujieda Y, et al. Nat Rev Rheumatol. 2019 Jun;15(6):324-325. doi: 10.1038/s41584-019-0218-6. Nat Rev Rheumatol. 2019. PMID: 31000789 No abstract available.
147 results